Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Aveo Pharmaceuticals (AVEO)

Aveo Pharmaceuticals (AVEO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 85,556
  • Shares Outstanding, K 16,082
  • Annual Sales, $ 5,410 K
  • Annual Income, $ -5,330 K
  • 60-Month Beta 0.73
  • Price/Sales 2.79
  • Price/Cash Flow N/A
  • Price/Book 4.50

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.60
  • Number of Estimates 3
  • High Estimate -0.40
  • Low Estimate -0.90
  • Prior Year -0.30
  • Growth Rate Est. (year over year) -100.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.65 +14.33%
on 01/31/20
6.30 -15.56%
on 01/27/20
-0.86 (-13.92%)
since 01/21/20
3-Month
4.65 +14.33%
on 01/31/20
8.20 -35.12%
on 12/02/19
-0.78 (-12.79%)
since 11/21/19
52-Week
4.65 +14.33%
on 01/31/20
18.50 -71.24%
on 04/02/19
-0.98 (-15.56%)
since 02/21/19

Most Recent Stories

More News
AVEO Announces Effectiveness of 1-for-10 Reverse Stock Split

AVEO Oncology (NASDAQ: AVEO) today announced that it will effect a 1-for-10 reverse stock split of its common stock that will be effective as of 5:00 p.m. Eastern Time today, February 19, 2020. AVEO's...

AVEO : 5.32 (+1.33%)
AVEO Oncology Announces Publication of Phase 1b/2 Study of Tivozanib in Advanced, Inoperable Liver Cancer in the British Journal of Cancer

AVEO Oncology (NASDAQ: AVEO) today announced the publication of results from a monotherapy trial of tivozanib, the Company's vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI),...

AVEO : 5.32 (+1.33%)
AVEO Posts Data on Ficlatuzumab From Pancreatic Cancer Study

AVEO releases results from a phase Ib study on ficlatuzumab in combination with nab-paclitaxel and gemcitabine for treating advanced pancreatic cancer. Shares inch up.

LLY : 142.04 (+0.03%)
AVEO : 5.32 (+1.33%)
PDLI : 3.48 (+0.29%)
DNLI : 24.45 (-1.29%)
AVEO Oncology and Biodesix Announce Results from Phase 1b Study of Ficlatuzumab, Gemcitabine and Nab-paclitaxel in Advanced Pancreatic Cancer

AVEO Oncology (NASDAQ: AVEO) and Biodesix, Inc. today announced the presentation of results from an investigator-sponsored Phase 1b trial of ficlatuzumab, AVEO's potent hepatocyte growth factor (HGF) inhibitory...

AVEO : 5.32 (+1.33%)
AVEO Announces Appointment of Erick J. Lucera as Chief Financial Officer

AVEO Oncology (NASDAQ: AVEO) today announced the appointment of Erick Lucera as chief financial officer. Mr. Lucera will be responsible for managing all aspects of the Company's financial and accounting...

AVEO : 5.32 (+1.33%)
Implied Volatility Surging for AVEO Pharmaceuticals (AVEO) Stock Options

Investors need to pay close attention to AVEO Pharmaceuticals (AVEO) stock based on the movements in the options market lately.

AVEO : 5.32 (+1.33%)
Why Is AVEO (AVEO) Down 0.1% Since Last Earnings Report?

AVEO (AVEO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

AVEO : 5.32 (+1.33%)
AVEO Oncology Announces Lancet Oncology Publication of Data from Phase 3 TIVO-3 Study of Tivozanib in Renal Cell Carcinoma

AVEO Oncology (NASDAQ: AVEO) today announced that previously reported data from its Phase 3 TIVO-3 study were published in The Lancet Oncology. TIVO-3 is the Company's Phase 3 randomized, controlled, multi-center,...

AVEO : 5.32 (+1.33%)
AVEO Oncology to Present at the 31st Annual Piper Jaffray Healthcare Conference

AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the 31st Annual Piper Jaffray Healthcare Conference in New York on Tuesday, December...

AVEO : 5.32 (+1.33%)
AVEO Oncology Announces Appointment of Scarlett Spring to its Board of Directors

AVEO Oncology (NASDAQ: AVEO) today announced the appointment of Scarlett Spring to its Board of Directors. Ms. Spring brings to AVEO extensive sales, commercial, and leadership experience in the biopharmaceutical...

AVEO : 5.32 (+1.33%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade AVEO with:

Business Summary

AVEO Pharmaceuticals, Inc. is a biopharmaceutical company engaged in discovering, developing and commercializing novel cancer therapeutics. Its product candidates are targeted against important mechanisms known or believed to be involved in cancer. Tivozanib, the Company's lead product candidate, is...

See More

Key Turning Points

2nd Resistance Point 5.55
1st Resistance Point 5.44
Last Price 5.32
1st Support Level 5.12
2nd Support Level 4.91

See More

52-Week High 18.50
Fibonacci 61.8% 13.21
Fibonacci 50% 11.58
Fibonacci 38.2% 9.94
Last Price 5.32
52-Week Low 4.65

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar